Advertising

The Seattle Times Company

NWjobs | NWautos | NWhomes | NWsource | Free Classifieds | seattletimes.com

The Seattle Times

Business / Technology


Our network sites seattletimes.com | Advanced

Originally published November 21, 2008 at 12:00 AM | Page modified November 21, 2008 at 9:06 AM

Comments (0)     E-mail article     Print view

Biotech startup GPC-Rx taps Accelerator venture capital

Seattle biotech startup GPC-Rx gets backing from the Accelerator to pursue drug design.

Seattle Times business reporter

The Accelerator seems to have struck gold in California.

The local incubator is investing in its second Seattle startup that uses technology developed at the California Institute of Technology.

The company, GPC-Rx, will focus on a new method to produce drugs that are more targeted than those on the market.

By designing therapies to zero in on certain receptors on the surface of cells, called GPCRs, the company hopes to hit a few home runs.

Many commercially available drugs work by targeting GPCRs, but the company says its drugs could be more precise and have fewer side effects. Its technology, which uses computer simulations of the structure of GPCRs, could also be used to design therapies of great complexity.

"Our greatest value is to do things that were impossible," said Bard Geesaman, who left a job as the executive director for life sciences of the X Prize Foundation in Boston to become GPC-Rx's chief scientific officer.

Many drug discoveries happen randomly. Caltech's technology could enable a rational method of selection that would significantly speed up the process of finding the right drug to treat a targeted ailment, said Accelerator Chief Executive Carl Weissman.

"We could skip all the hit-and-miss discovery stage," he said.

GPC-Rx is one of the Accelerator's "most substantial investments," Weissman said.

Typically, the incubator invests between $1.5 and $5 million into fledgling firms.

Although Weismann declined to disclose the sum, he said it's in the upper end of that range.

GPC-Rx will need the money to contract with outside medical chemists and to pay for the massive computing power required to simulate potential therapies.

advertising

This round of funding is expected to last until the company puts a product into clinical testing, at least two years away.

GPC-Rx will be based in the Accelerator's Eastlake building.

Other than Geesaman, the startup will hire two or three key employees as it builds its way toward clinical trials in humans.

Dr. William Goddard of Caltech, who co-founded Allozyne along with the Accelerator in 2005, is also behind this venture.

Allozyne has so far proved a success, moving out of the Accelerator's nest and raising some $30 million last year.

"We're more than doubling down" on Caltech's technology, Weissman said.

Ángel González: 206-515-5644 or agonzalez@seattletimes.com

Copyright © 2008 The Seattle Times Company

More Business & Technology headlines...

E-mail article Print view      Share:    Digg     Newsvine

Comments
No comments have been posted to this article.

An 802.11n upgrade could make a big difference

Retailers opening doors on Thanksgiving Day

Google makes concessions on digital book deal

Critics want to block Comcast-NBC deal

Google submits revised book settlement

Advertising

Video

Opening day at Crystal Mountain
Skiers crowded the slopes at Crystal Mountain for one of the resort's earliest openings.

Video shows violent arrest by SPD
Fort Lewis Memorial
Highlights: Ken Auletta talks about "Googled"
Seattle International Cabaret Festival
Ken Auletta talks about "Googled"
Medal of Honor
Pelosi answers questions at Swedish Medical Center
Pelosi speaks at Swedish Medical Center
"Pistol" Pete Ryan

Marketplace

nwautos

2009's most fuel-efficient sedansnew
Choosing a new sedan? Weigh the impact of your choice on your wallet and on the planet.
Post a comment

Open Houses

Find this weekend's open house listings.
Or search by location:

 
Most read
Most commented
Most e-mailed
 
 
Advertising